Growth Funding Series B financing of 42M oversubscribed signals strong investor confidence and available capital to scale the Hēlo thrombectomy platform, presenting an opportunity for potential strategic partnerships, expanded clinical development collaborations, and enterprise-level procurement discussions.

Clinical Progress Positive ENGULF study results for Hēlo thrombectomy system indicate a progressing clinical validation path, creating a sales window for device adoption discussions with hospital systems, vascular centers, and integrated delivery networks seeking evidence of efficacy and safety.

Leadership Momentum New CEO appointment suggests strategic realignment and growth focus, offering a contact point for executive-level discussions on partnerships, pilot programs, and joint go-to-market initiatives with larger medical device distributors.

Venous Thromboembolism Focus Dedicated mission to venous thromboembolism clot removal aligns with unmet needs in VTE care, enabling targeted outreach to specialists, hospitals, and payers seeking innovative endovascular solutions with potential cost and workflow benefits.

Financial Scale & Fit Current revenue in the 10–25 million range and overall funding of 137 million place E2 as a fast-growing mid-stage player that can be positioned for tiered procurement deals, co-development programs, and strategic investment discussions with mid to large-cap medical device companies.